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Objectives The present study was designed to assess the effect of genetic variants on chronic bio-
logical response to prasugrel and bleeding complications.
Background CYP2C19*2 loss-of-function allele and CYP2C19*17 gain-of-function allele have been
inked with response to clopidogrel, but preliminary data did not show any signiﬁcant inﬂuence of
hese alleles on prasugrel effect.
ethods A total of 213 patients undergoing successful coronary stenting for acute coronary syn-
rome and discharged with prasugrel 10 mg daily were included. Prasugrel response was assessed
t 1 month with the platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) and
igh on-treatment platelet reactivity (HTPR) deﬁned as PRI VASP  50% and hyper-response as PRI
ASP 75th percentile (PRI VASP  17%). CYP2C19*2 and CYP2C19*17 genotyping were performed.
esults Carriers of loss-of-function *2 allele had signiﬁcantly higher PRI VASP than noncarriers (33 
5% vs. 27  14%, p  0.03) and higher rate of HTPR (16% vs. 4%, p  0.01). Conversely, carriers of
*17 gain-of-function allele had signiﬁcantly lower PRI VASP than noncarriers (25  13% vs. 31  15%,
p  0.03, p  0.03), lower rate of HTPR (1% vs. 10%, p  0.02), higher rate of hyper-response (34% vs.
21%, p  0.02), and higher rate of bleeding complications than noncarriers: 23% versus 11%, (odds ratio
[95% conﬁdence interval]: 2.5 [1.2 to 5.4]; p  0.02). No signiﬁcant inﬂuence of genotypes on platelet
reactivity assessed by adenosine diphosphate–induced platelet aggregation was observed.
Conclusions The present study shows a signiﬁcant inﬂuence of CYP2C19*2 and *17 alleles on response
to chronic treatment by prasugrel 10 mg daily and occurrence of bleeding complications. (J Am Coll
Cardiol Intv 2012;5:1280–7) © 2012 by the American College of Cardiology Foundation
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1281Dual antiplatelet therapy with aspirin and clopidogrel has been
the gold standard therapy for patients undergoing percutane-
ous coronary interventions (PCI) and/or after acute coronary
syndrome (ACS) (1–3). The large variability of the clopidogrel
response has been described with clinical consequences (4).
fter intestinal absorption, clopidogrel biotransformation into
ts active metabolite is mainly mediated by hepatic cytochrome
450 (CYP). Recent data showed that the CYP2C19*2 loss-
f-function allele is associated with a marked decrease in
latelet response to clopidogrel in unstable patients (5) and an
mpaired prognosis in clopidogrel-treated patients (6,7). By
ontrast, the gain-of-function allele CYP2C19*17 has been
inked with a better response to clopidogrel (8) and, accordingly,
higher risk of bleeding (9). Recently, a third-generation thien-
pyridine, prasugrel, has provided faster, more potent and predict-
ble platelet inhibition compared with clopidogrel (10,11). This
igher degree of platelet inhibition resulting in a significant
eduction of ischemic events was associated with an increase of
leeding complications in the overall TRITON TIMI 38 (Trial
o Assess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition with Prasugrel–Thrombolysis in Myocardial
nfarction) study (12). Like clopidogrel, it is a prodrug that
rreversibly blocks the P2Y12 platelet receptor after hepatic trans-
ormation and could be affected by CYP450 genetic variants.
owever, previous studies did not find any significant influence of
YP genetic variants on pharmacokinetic and pharmacodynamic
esponse to prasugrel and on clinical outcome in prasugrel-treated
atients (13,14), although a trend was observed in the Mega et
l. study (13). These studies included both ACS patients and
ealthy subjects, assessed response to 60-mg loading dose, and
sed light transmittance aggregometry (LTA) as the platelet
est, though the influence of such genetic variants on response
o maintenance therapy in ACS patients using the most
pecific test of P2Y12 inhibition, the platelet reactivity index
PRI) vasodilator-stimulated phosphoprotein (VASP), re-
ained unknown. We therefore designed the present study to
ssess the influence of CYP2C19*2 and *17 alleles on prasugrel
response and bleeding complications in patients treated with
prasugrel 10 mg daily after PCI for ACS.
Methods
Study population. Consecutive patients admitted for non–
T-segment elevation ACS or ST-segment elevation myocar-
ial infarction in our institution were eligible for this prospec-
ive study if they had undergone successful PCI and were
reated at discharge with prasugrel 10 mg. The exclusion
riteria were a history of bleeding diathesis, prior stroke or
ransient ischemic attack, contraindications to antiplatelet ther-
py, platelet count100 109/l, and creatinine clearance25
l/min. Patients received loading doses of aspirin 250 mg and
rasugrel 60 mg and, as discharge therapy, oral doses of 75-mg
spirin and 10- mg prasugrel daily. Prasugrel response wasssessed at 1-month clinical follow-up by PRI VASP. Adher-
nce was systematically assessed during this consultation. The
tudy protocol was approved by the ethics committee of our
nstitution, and patients gave written informed consent for
articipation.
Platelet parameters. Blood samples for testing clopidogrel
response were drawn at 1-month follow-up. For patients
who experienced significant bleeding (Bleeding Academic
Research Consortium [BARC] 2) and who needed to stop
rasugrel, platelet testing was performed in our center before
iscontinuation. Blood was sent immediately to the hemostasis
aboratory to determine the
ASP phosphorylation state of
hole blood. We used a standard-
zed flow cytometric assay (Plate-
et VASP; Diagnostica Stago/
iocytex, Asnières, France),
hich is an adaptation of the
ethod of Schwarz et al. (15)
reviously described. PRI VASP
as calculated from the median
uorescence intensity (MFI) of
amples incubated with prosta-
landin E1 (PGE1) or PGE1 and
adenosine diphosphate (ADP) ac-
cording to the formula: PRI
VASP  [(MFI( P G E 1 ) 
FI(PGE1ADP)/MFIPGE1] 
00. High on-treatment platelet
eactivity (HTPR) was defined as
RI VASP 50% as recently
roposed (16), and hyper-
esponse as PRI VASP below the
5th percentile by quartile repar-
ition. Blood was immediately
ollected in an evacuated blood
ample tube containing 3.8%
risodium citrate and filled to ca-
acity. The blood–citrate mixture
as centrifuged at 120 g for 5
min. The resulting platelet-rich
plasma was kept at room temper-
ature for use within 1 h. The
platelet count was determined in the platelet-rich plasma
sample and adjusted to 2.5  108 ml1 with homologous
platelet-poor plasma. Platelets were stimulated with ADP (10
mol/l) and aggregation was assessed with a PAP4 Ag-
gregometer (Biodata Corporation, Wellcome, Paris, France).
Aggregation was expressed as the percentage change in light
transmittance from baseline, with platelet-poor plasma as
reference. Here, we report data on the maximal intensity of
ADP-induced platelet aggregation (ADP-Ag). The coefficient
of variation of maximal intensity of platelet aggregation with
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
ADP-Ag  adenosine
diphosphate–induced platelet
aggregation
BARC  Bleeding Academic
Research Consortium
CI  confidence interval
CYP  cytochrome P450
HTPR  high on-treatment
platelet reactivity
LTA  light transmittance
aggregometry
OR  odds ratio
MFI  median fluorescence
intensity
PCI  percutaneous
coronary interventions
PCR  polymerase chain
reaction
PGE1  prostaglandin E1
PRI  platelet reactivity
index
TIMI  Thrombolysis In
Myocardial Infarction
VASP  vasodilator-
stimulated phosphoproteinADP was measured at 6.5%.
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1282Genotyping. Genomic DNA was extracted from peripheral
lood leukocytes by the salting-out method. CYP2C19*2
nd CYP2C19*17 genotyping was done using amplification
refractory mutation system PCR in duplex reaction. Primers
(Invitrogen, Carlsbad, California) are as follows: *2 forward:
cag agc ttg gca tat tgt atc, *2 reverse: tat cgc aag cag tca cat
ac; *2 G specific (sense): act atc att gat tat ttc ccg and *2 A
pecific (antisense): gta att tgt tat ggg ttc ct; *17 forward: aag
ag cct tag ttt ctc aag, *17 reverse: aaacacctttaccatttaaccc; *17
specific (sense): tgt ctt ctg ttc tca aag ta and *17 C specific
antisense): atta tct ctt aca tca gag atg. Size of the PCR
roducts generated: CYP2C19*2 forward/reverse: 373 bp, *2
llele G (normal): 283 bp, and *2 allele A (mutated): 129 bp;
YP2C19*17 forward/reverse: 507 bp, *17 allele C (normal):
30 bp, and *17 allele T (mutated): 218 bp. Reactions were
ade in a final volume of 12.5 l, using 200 nmol/l of
primer except for *2 A primer (300 nmol/l), 0.15 unit of Taq
DNA polymerase (Qbiotaq, MP Biomedicals, Solon, Ohio)
in its accompanying buffer, 200 m of accompanying
eoxyribonucleotide triphosphates, and 25 ng of genomic
NA. Cycling conditions: first denaturing step: 90 min at
4°C, then 35 cycles of 30 min at 95°C, 30 min at 60°C, and
0 min at 72°C, final extension step: 3 h at 72°C and then
ooling to 15°C. PCR products were run on 2% agarose
els, and genotypes were assigned according to the PCR
roducts sizes observed. CYP2C19*2 and *17 are defined by
rs4244285 and rs12248560, respectively. Hardy-Weinberg
equilibrium was tested for each polymorphism to detect
potential stratification bias or genotyping errors.
Clinical follow-up. Clinical follow-up was planned for all
atients at 1 month. The clinical endpoint was the occurrence
f bleeding events according to the BARC consensus defini-
ions with Type 1 and 2 or 3 or 5 (Type 4 was not expected
ecause no patient had planned coronary artery bypass graft-
ng) (17). Bleeding complications according to the Thrombol-
sis In Myocardial Infarction (TIMI) definition were also
ollected (12). Ischemic events were also collected using the
ombined endpoint of cardiovascular death, myocardial infarc-
ion, definite or probable stent thrombosis, and stroke. Definite
r probable stent thrombosis was defined as the definite
ccurrence of a thrombotic event, according to the Academic
esearch Consortium classification (18). To be considered a
rimary endpoint event, a myocardial infarction must be
istinct from the index event and defined with the universal
efinition of myocardial infarction (19). Stroke was defined as
rapid onset of a new persistent, neurological deficit that lasts
or more than 24 h.
Endpoints. The primary endpoint of the present study was
he effect of CYP2C19*2 and *17 allele on prasugrel response
ssessed by PRI VASP, incidence of HTPR defined as PRI
ASP  50%, and hyper-response defined as PRI VASP
elow the 75th percentile. Secondary endpoints assessed the
leeding complications and influence of both prasugrel
esponse and genotypes on bleeding risk.Statistical analysis. Statistical analysis was performed using
the GraphPad Prism Software (v. 4.00, GraphPad Software,
La Jolla, California). Continuous variables were analyzed for
a normal distribution with the Shapiro-Wilk test and
expressed as mean  SD. Categorical variables are expressed
as frequencies and percentages. Comparisons between groups
were made with the chi-square or Fisher exact test for
categorical variables and t test for continuous variables. One-
ay analysis of variance was used for comparison between
ifferent groups. Values of p  0.05 were considered statisti-
ally significant. Assuming that carriers of *2 and *17 alleles
epresent one-third of the entire population, and expecting in
hese patients a 5% absolute difference in PRI VASP compared
ith patients who were noncarriers, a total of at least 205
atients were needed to detect the expected difference with an
stimated power of 80% at a 2-sided alpha of 0.05.
esults
A total of 213 patients undergoing successful PCI for ACS
and discharged with prasugrel 10 mg daily were prospec-
tively included. Characteristics of the studied population are
included in Table 1. In the whole population, the rate of
patients with HTPR was 7% (n  15). The present study
included 15 patients (7%) older than 75 years, and 13
patients (6%) with low body weight. Prasugrel response
(PRI VASP) and platelet reactivity (ADP-Ag) were not
statistically different in these subgroups of patients. Neither
PRI VASP nor clinical bleeding events differed by smoking
Table 1. Patients Characteristics (N  213)
Age, yrs 58 10
Women 23 (11)
Clinical presentation
NSTE ACS 117 (55)
STEMI 96 (45)
Weight, kg 82 15
Body mass index, kg/m2 32 7
Hypertension 83 (39)
Diabetes 64 (30)
Smoker 106 (50)
Dyslipidemia 104 (49)
Familial history 36 (17)
Previous CAD 63 (30)
Prior antiplatelet
therapy
68 (32)
Beta-blockers 164 (77)
PPI 209 (98)
Statins 207 (97)
LV ejection fraction 55 7
Creatinine, mol/l 92 54
Values are n (%) or mean SD.
ACS  acute coronary syndrome; CAD  coronary artery disease; LV  left ventricular;
NSTE  non–ST-segment elevation; PPI  proton pump inhibitor; STEMI  ST-segmentelevation myocardial infarction.
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1283status, unlike published reports regarding clopidogrel. The
genotype frequencies for each allele considered separately
were consistent with Hardy-Weinberg predictions, and
genetic distributions are reported in Table 2.
Effect of genotypes on prasugrel response (PRI VASP). At 1
onth, patient who were carriers of loss-of-function *2
llele had significantly higher PRI VASP than noncarriers
33 15% vs. 27 14%, p 0.03, Fig. 1) and a higher rate
f HTPR (16% vs. 4%, p  0.01, Fig. 2A). Conversely,
atients who were carriers of *17 gain-of-function allele had
ignificantly lower PRI VASP than noncarriers (25  13%
s. 31  15%, p  0.03, Fig. 1) and lower risk of HTPR
1% vs. 10%, p  0.02, Fig. 2B). We defined hyper-
esponse as PRI VASP below the 75th percentile of the
opulation by quartile repartition, identifying a threshold of
RI VASP 17%. In the whole cohort, 55 patients (26%)
ere hyper-responders. Incidence of hyper-response was
ignificantly higher among carriers of *17 gain-of-function
Table 2. Genetic Distribution of the CYP 2C19*2 Loss-of-Function
and CYP2C19*17 Gain-of-Function Polymorphisms (n  213)
Polymorphism Genetic Distribution
CYP2C19*2 AA: 1 (1%)
AG: 49 (23%)
GG: 163 (76%)
CYP2C19*17 TT: 11 (5%)
CT: 62 (29%)
TT: 139 (65%)
Values are n (%).
CYP cytochrome P450.
Figure 1. Prasugrel Response According to Genotypes
PRI VASP according to CYP2C19*2 and CYP2C19*17 status (n  213). PRI H
platelet reactivity index; VASP  vasodilator-stimulated phosphoprotein.llele than in noncarriers: 34% (n  25 of 73) versus 21%
n  30 of 140), p  0.02 (Fig. 3).
Effect of genotypes on platelet reactivity (LTAwith ADP-Ag). At
1 month, patients who were carriers of loss-of-function *2
allele did not have significantly higher ADP-Ag values than
noncarriers (48  15% vs. 46  14%, p  0.78), and
patients who were carriers of *17 gain-of-function allele did
not have significantly lower ADP-Ag values than noncar-
riers (45  13% vs. 48  14%, p  0.36).
Classiﬁcation of patients according to genotypes: interaction
of *2 and *17 alleles. Given the significant association
etween PRI VASP and genetic variants, patients were
lassified according to their genotypes as poor metabolizers
*2 loss-of-function allele carriers/*17 gain-of-function allele
oncarriers) (n  42), intermediate metabolizers (*2 loss-
f-function allele carriers/*17 gain-of-function allele carriers
r *2 loss-of-function allele noncarriers/*17 gain-of-
unction allele noncarriers) (n 107), and ultrametabolizers
*2 loss-of-function allele noncarriers/*17 gain-of-function
llele carriers) (n  64).
This classification was associated with the mean PRI
ASP values and with the incidence of HTPR on prasugrel
0 mg (Figs. 4A and 4B). Indeed, the rate of patients with
Figure 2. Incidence of HTPR According to CYP2C19*2 and
CYP2C19 Status
High on-treatment platelet reactivity (HTPR) deﬁned as PRI VASP  50%
according to (A) CYP2C19*2 status and (B) CYP2C19*17 status (n  213).
Abbreviations as in Figure 1.TPR was 19% in poor metabolizers (n  8 of 42), 6% in
o
i
b
a
V
v
h
c
r
o
p
d
i
g
c
h
r
0
t
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 2 , 2 0 1 2
D E C E M B E R 2 0 1 2 : 1 2 8 0 – 7
Cuisset et al.
Genetic and Prasugrel Response
1284intermediate metabolizers (n  6 of 107), and 1% in
ultrametabolizers (n  1 of 64) (Fig. 4B) (p  0.002). For
the rate of hyper-response, we observed a trend with a
numerically higher rate of hyper-response of 14% in poor
Figure 3. Incidence of Hyper-Response According to CYP2C19*17 Status
Incidence of hyper-response deﬁned as PRI VASP 17% according to
CYP2C19*17 status (PRI VASP 75th percentile, quartile repartition). Abbre-
viations as in Figure 1.
Figure 4. Prasugrel Response According to Genotype Group
Values of PRI VASP on prasugrel 10 mg (A) and incidence of prasugrel low
response (HTPR deﬁned as PRI VASP  50%) (B) according to genotype
groups between poor metabolizers (*2 carriers/*17 noncarriers) (n  42),
intermediate metabolizers (*2 carriers/*17 carriers and *2 noncarriers/*17
noncarriers) (n  107), and ultrametabolizers (*2 noncarriers/*17 carriers)m
(n  64). Abbreviations as in Figures 1 and 2.metabolizers (n  6 of 42), 24% in intermediate metabo-
lizers (n 26 of 107), and 36% in ultrametabolizers (n 23
of 64) (p  0.10).
Clinical outcomes. In the overall population, the incidence
f bleeding complications at 1 month was 15% (n  32),
ncluding 16 BARC 1, 13 BARC 2, and 3 BARC 3
leeding events. Patients who had bleeding complications
ccording to BARC definitions had significantly lower PRI
ASP than patients without complications: 24  14%
ersus 30.1  14% (p  0.03) (Fig. 5). Patients with
yper-response had a significantly higher rate of bleeding
omplications compared with patients without hyper-
esponse: 24% (n  13 of 55) versus 12% (n  19 of 158),
dds ratio (OR) [95% confidence interval (CI)]: 2.2 [1 to 5];
 0.04) (Fig. 6). Values of ADP-Ag were not significantly
ifferent between patients with and without BARC bleed-
ng complications (data not shown). For the impact of
enetic variants on clinical outcomes; patients who were
arriers of *17 gain-of-function allele had a significantly
igher rate of BARC bleeding complications than noncar-
iers: 23% versus 11%, (OR [95% CI]: 2.5 [1.2 to 5.4]; p 
.02) (Fig. 7). In the different groups according to geno-
ypes, we observed a nonsignificant trend for the distribu-
ion of bleeding complications: 10% (n  4) in poor
Figure 5. Prasugrel Response and Bleeding
Prasugrel response among patients with or without bleeding complications.
Abbreviations as in Figure 1.etabolizers, 14% (n  15) in intermediate metabolizers,
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1285and 20% (n  13) in the ultrametabolizers group (p 
0.20).
During the 1-month follow-up, we observed only 2
ischemic events, including 1 definite and 1 probable stent
thrombosis. Genetic and platelet parameters were not sig-
nificantly different among patients with or without ischemic
events (data not shown). Using the TIMI definition for
bleeding complications, only 1 TIMI major bleeding and 7
TIMI minor bleeding occurred during the follow-up, with-
out statistical significant association with genotypes or
platelet testing.
Discussion
In the present study, we observed a significant effect of
CYP2C19*2 and *17 alleles on prasugrel response and
leeding events in patients treated with 10 mg daily after
CI for ACS. This study provides for the first time, to the
est of our knowledge, data about CYP2C19 genetic
olymorphisms’ modulation of platelet response and bleed-
ng risk in prasugrel-treated patients after ACS.
A large amount of data has demonstrated the influence of
YP2C19*2 loss-of-function allele on platelet response to
lopidogrel in unstable patients (5) and an impaired prog-
osis in clopidogrel-treated patients (6,7). By contrast, the
ain-of-function *17 allele was described as associated with
better response to clopidogrel (8) and higher risk of
leeding (9). Recently, a third-generation thienopyridine,
rasugrel, provides a faster, more potent and predictable
latelet inhibition compared with clopidogrel (10,11). This
igher degree of platelet inhibition resulting in a significant
eduction of ischemic events was associated with an increase
f bleeding complications in the TRITON TIMI 38 study
Figure 6. Hyper-Response and Bleeding
Incidence of bleeding complications among patients with hyper-response
(PRI VASP 17%) and others. Abbreviations as in Figure 1.12). Indeed, in the present study, we observed a morepredictable degree of platelet inhibition with prasugrel with
a low rate of patients with residual HTPR while treated
with prasugrel. These results are not in line with those
previously published by Bonello et al. (16) showing a
significant proportion of patients with HTPR after the 60
mg loading dose. This discrepancy illustrates that a remain-
ing critical issue of platelet testing is the timing and delay
from loading dose to sampling for antiplatelet therapy
monitoring. A possible explanation of the observed findings
(16), is that the delay between loading dose and sampling
was too short to allow appropriate effectiveness of the
treatment. In a substudy of TRITON-TIMI 38, Michelson
et al. (20) found that 24% patients had HTPR at 1 month
on prasugrel 10 mg daily. This discrepancy could be
explained by the patient characteristics, with higher body
mass index and incidence of diabetes in the Michelson’s
study (20). Recently, results from several studies performed
were in line with our results, with a low rate (10%) of
patients with HTPR while treated with prasugrel 10 mg
daily (21–23). However, in the present study, we still
observed variability of response to prasugrel, which could be
explained by the relatively high incidence of factors known
to influence thienopyridine metabolism, including prasug-
rel, such as acute myocardial infarction, diabetes, and
patients with a high body mass index.
Like clopidogrel, prasugrel is a prodrug that irreversibly
blocks the P2Y12 platelet receptor after hepatic transforma-
tion and could be affected by CYP450 genetic variants.
Previous studies found a significant influence of CYP
genetic variants on pharmacokinetic and pharmacodynamic
response to clopidogrel, but not to prasugrel (13,14), al-
though a trend was observed in the Mega et al. study (13),
suggesting that the absence of difference might be due to a
lack of power in 238 healthy volunteers (13,14). However,
these studies included mainly healthy subjects, assessed
biological response to 60-mg prasugrel loading dose, and
Figure 7. Bleeding and CYP2C19*17 StatusIncidence of bleeding complications according to CYP2C19*17 status.
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1286used LTA as platelet test. Moreover, the CYP2C19*17 allele
as not included in the genetic subanalysis of the TRITON
tudy (13). Our present results are in line with those
reviously published studies (13,14) observing no significant
ssociation between on-prasugrel platelet reactivity assessed
y ADP-Ag and these genetic variants. However, we
riginally observed a significant effect of CYP2C19 geno-
ypes on prasugrel response assessed by PRI VASP. Among
ach genotype, we still observed a large variability of platelet
esponse to prasugrel. This finding highlights the fact that
rasugrel response, as described for clopidogrel response, is
multifactorial process and that genetic modulation is only,
lthough strong, 1 factor explaining variability of response
24). We thus observed in our study a clear discordance
etween the effect of genetic variants on platelet reactivity
ADP-Ag) and prasugrel response (PRI VASP). For years,
everal platelet tests have been proposed to assess response
o thienopyridine. In clopidogrel-treated patients, different
ests have significant correlation but their agreement to
dentify specific patients as responders or not are rather low
25). Accordingly, the gold standard test to assess response
o thienopyridine is still controversial, and the best option to
redict clinical outcomes between a specific pharmacological
est (PRI VASP) and more “global” assessment of platelet
eactivity (LTA, VerifyNow) is still unclear. In the impor-
ant POPULAR (Do Point-of-Care Platelet Function As-
ays Predict Clinical Outcomes in Clopidogrel Pre-Treated
atients Undergoing Elective PCI) study (26), various
latelet tests were tested to assess clinical outcomes. Only
ome of the tests used were able to predict ischemic events,
uggesting different performances of platelet tests to predict
linical outcome. Our results, focusing on prasugrel-treated
atients, are in line with this study; only PRI VASP was
ignificantly associated with bleeding events, suggesting
RI VASP as the best option for bleeding risk prediction
ith prasugrel. Indeed, it is interesting to note that
DP-Ag is scarcely lower than 20%, in contrast to PRI-
ASP, which may reach 0%, indicating a limit of ADP-Ag
o detect strong degree of P2Y12 inhibition, suggesting PRI
ASP as the best option in patients treated with strong
2Y12 inhibitors to assess platelet response and bleeding
isk. Accordingly, although ADP-Ag has a greater amount
f evidence for a relationship with ischemic events (4), PRI
ASP might be a better test to assess bleeding risk with new
2Y12 blockers providing a strong degree of P2Y12 path-
ay inhibition. In the present study, we also introduced the
otion of hyper-response to prasugrel, incorporating a new
oncept with a threshold value for PRI VASP and identi-
ying hyper-responder patients with high bleeding risk with
ew P2Y12 blockers. Together with HTPR defined with
lopidogrel as PRI VASP50% (16), this might suggest an
ptimal therapeutic window (17% to 50%) for patients
reated with P2Y12 inhibitors.Also, results on LTA might have been due to the amount
of ADP used (10 mol/l), which is an intermediate dose of
ADP to stimulate platelets highly inhibited by a P2Y12
antagonist. The 20 mol/l dose might be more appropriate
s shown in the ALBION (Assessment of the Best Loading
ose of Clopidogrel to Blunt Platelet Activation, Inflam-
ation and Ongoing Necrosis) study with clopidogrel (27).
n addition, for prasugrel metabolism, in vitro studies
ndicate the active prasugrel metabolite generation occurs
rimarily by CYP3A and CYP2B6 with lesser contributions
y CYP2C9 and CYP2C19 (28). However, our present
esults suggest that CYP2C19 participates in active metab-
lite formation.
Clinical relevance of such findings will have to be
ddressed in further clinical trials, including high-risk pa-
ients and all genetic variants thought to influence clinical
rognosis. Indeed, the potential effect of CYP2C19*17 on
leeding risk in prasugrel-treated patients could be of great
linical interest, aiming to provide genetic-based individu-
lized therapy. In the present study, we included BARC 1
leedings in the analysis. These bleedings might not be
linically meaningful by themselves and could be considered
s minimal or nuisance bleedings. However, these events
ight lead to premature discontinuation of the drug in daily
ractice as shown in clopidogrel- and prasugrel-treated
atients (29,30). Also, this study emphasizes the fact that
latelet function test and genotyping may be complemen-
ary to assess both ischemic and bleeding risk. It also shows
hat genetics are important when using a thienopyridine,
ither clopidogrel or prasugrel, and that risk scoring with
enetic information might be useful also for bleeding risk as
hown for stent thrombosis in the recently published paper
y Cayla et al. (31). Accordingly, genetically tailored ther-
py could be tested with switching poor metabolizers to
rasugrel and fast metabolizers to clopidogrel. However, the
linical benefit of such a strategy should be tested in further
andomized clinical trials, whereas data on a switch are only
vailable from biological studies (32,33).
Study limitations. The main limitation of the present study
is its limited sample size and the lack of power to detect an
effect on endpoint, such as mortality or stent thrombosis.
Also, effect on bleeding was observed with inclusion of
minimal BARC 1 bleedings. Finally, assessment of response
to chronic antiplatelet therapy may have been modified by
lack of compliance. However, in the present study, efforts
were made to improve compliance and to detect noncom-
pliant patients.
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